Mecasermin (Recombinant IGF-1) from Japan
Mecasermin is recombinant insulin-like growth factor 1 (IGF-1), a structural analogue closely related to the somatotropin/IGF-1 axis used in severe primary IGF-1 deficiency. While IGF-1 mediates somatotropin effects, its classification follows chapter notes for hormone analogues. HTS 2937.11.00.00 includes such polypeptide hormones used primarily in growth regulation.
Duty Rate — Japan → United States
15%
Rate breakdown
9903.04.6215%Pharmaceuticals: patented pharma from JP/EU/KR/CH/LI — 15% floor rate
9903.05.860%Universal product exemption (U.S. note 52(b))
9903.05.900%Articles already subject to Section 232 (steel/aluminum/copper + derivatives, autos + parts, wood, medium/heavy vehicles + parts, semiconductors, patented pharma) — U.S. note 52(f)
Import Tips
• Include documentation linking IGF-1 to somatotropin pathway for classification justification
• Ensure compliance with pediatric growth hormone therapy import protocols
• Provide purity certificates (>95%) and endotoxin testing results